Short answer
OmniAb, Inc. (OABI) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $2M (down 46.3% year over year) with net income of −$17M.
Q3 2025 key financials · XBRL
- Revenue
- $2M
- −46.3% YoY · −42.5% QoQ
- Net income
- −$17M
- −0.9% YoY · −4.1% QoQ
- Operating margin
- -810.2%
- EPS (diluted)
- −$0.14
- +12.5% YoY · +6.7% QoQ
Source: XBRL data from the OmniAb, Inc. (OABI) Q3 2025 10-Q on SEC EDGAR. USD.
OmniAb, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $2.239M, down 46% YoY from $4.172M
- Royalty revenue best-performing line at $361K, up 14% YoY; license and milestone revenue worst at $616K, down 55%
- Net loss $16.525M vs $16.373M; effective tax rate (6.6)% vs (14.2)%
- Cash, equivalents and short-term investments $59.5M; operating cash use $30.8M through nine months vs $35.8M
- August PIPE generated approximately $30.0M gross proceeds; cash runway expected through at least next 12 months
Risk Factors
- Medicaid funding reductions under the One Big Beautiful Bill Act, enacted July 2025, threatening partners’ product sales
- Federal most-favored-nation pricing threats and drug-cost regulations potentially reducing partners’ commercial revenues
- State prescription drug affordability boards and price-cap initiatives limiting drug prices or complicating distribution
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other OmniAb, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.